U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C15H21NO2.ClH
Molecular Weight 283.794
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MEPERIDINE HYDROCHLORIDE

SMILES

Cl.CCOC(=O)C1(CCN(C)CC1)C2=CC=CC=C2

InChI

InChIKey=WCNLCIJMFAJCPX-UHFFFAOYSA-N
InChI=1S/C15H21NO2.ClH/c1-3-18-14(17)15(9-11-16(2)12-10-15)13-7-5-4-6-8-13;/h4-8H,3,9-12H2,1-2H3;1H

HIDE SMILES / InChI
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C15H21NO2
Molecular Weight 247.3327
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: http://www.pbm.va.gov/clinicalguidance/criteriaforuse/MeperidineCriteriaforUse.pdf | https://www.drugs.com/pro/meperidine.html

Pethidine, also known as meperidine and Demerol, a narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Meperidine is an opioid agonist with multiple actions qualitatively similar to those of morphine. Most common adverse reactions were lightheadedness, dizziness, sedation, nausea, vomiting, and sweating. Pethidine has serious interactions that can be dangerous with monoamine oxidase inhibitors (e.g., furazolidone, isocarboxazid, moclobemide, phenelzine, procarbazine, selegiline, tranylcypromine). Pethidine can interact with muscle relaxants, some antidepressants, benzodiazepines, and ethanol.

CNS Activity

Originator

Approval Year

1942
37
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2752
 450.1 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
DEMEROL

Approved Use

For the relief of moderate to severe pain. For preoperative medication. For support of anesthesia. For obstetrical analgesia.

Launch Date

1942
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
196 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/2891328/
30 mg single, intravenous
dose: 30 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MEPERIDINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
19.6 μg × min/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/2891328/
30 mg single, intravenous
dose: 30 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MEPERIDINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
124 min
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/2891328/
30 mg single, intravenous
dose: 30 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MEPERIDINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
10 g single, oral
Overdose
Dose: 10 g
Route: oral
Route: single
Dose: 10 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/17364646
unknown, 17 years
Health Status: unknown
Age Group: 17 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/17364646
Other AEs: Respiratory depression, Hypotension...
Other AEs:
Respiratory depression (1 patient)
Hypotension (1 patient)
Tremor (1 patient)
Hyperreflexia (1 patient)
Myoclonus (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/17364646
50 mg single, intrathecal
Dose: 50 mg
Route: intrathecal
Route: single
Dose: 50 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/7923521
unknown, 24 - 81 years
Health Status: unknown
Age Group: 24 - 81 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/7923521
Other AEs: Respiratory depression...
Other AEs:
Respiratory depression (2 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/7923521
1000 mg 1 times / day multiple, intramuscular
Highest studied dose
Dose: 1000 mg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 1000 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3941530/
unhealthy, 37 years
Health Status: unhealthy
Age Group: 37 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/3941530/
Disc. AE: Muscle twitching, Tremor...
AEs leading to
discontinuation/dose reduction:
Muscle twitching (1 patient)
Tremor (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/3941530/
600 mg 1 times / day multiple, intravenous
Highest studied dose
Dose: 600 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11772223
unknown, 44 years
Health Status: unknown
Age Group: 44 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/11772223
Other AEs: Jitteriness, Hallucinations...
Other AEs:
Jitteriness (3 patients)
Hallucinations (3 patients)
Seizures (3 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/11772223
50 mg 6 times / day multiple, intramuscular
Recommended
Dose: 50 mg, 6 times / day
Route: intramuscular
Route: multiple
Dose: 50 mg, 6 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
pregnant, adult
Health Status: pregnant
Age Group: adult
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
Other AEs: Withdrawal syndrome neonatal...
Other AEs:
Withdrawal syndrome neonatal
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
50 mg 6 times / day multiple, oral
Recommended
Dose: 50 mg, 6 times / day
Route: oral
Route: multiple
Dose: 50 mg, 6 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/005010s059lbl.pdf
pregnant, adult
Health Status: pregnant
Age Group: adult
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/005010s059lbl.pdf
Other AEs: Withdrawal syndrome neonatal...
Other AEs:
Withdrawal syndrome neonatal
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/005010s059lbl.pdf
50 mg 6 times / day multiple, subcutaneous
Recommended
Dose: 50 mg, 6 times / day
Route: subcutaneous
Route: multiple
Dose: 50 mg, 6 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
pregnant, adult
Health Status: pregnant
Age Group: adult
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
Other AEs: Withdrawal syndrome neonatal...
Other AEs:
Withdrawal syndrome neonatal
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
50 mg 6 times / day multiple, intramuscular
Recommended
Dose: 50 mg, 6 times / day
Route: intramuscular
Route: multiple
Dose: 50 mg, 6 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
Other AEs: Addiction, Respiratory depression...
Other AEs:
Addiction
Respiratory depression (serious|grade 5)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
50 mg 6 times / day multiple, oral
Recommended
Dose: 50 mg, 6 times / day
Route: oral
Route: multiple
Dose: 50 mg, 6 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/005010s059lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/005010s059lbl.pdf
Other AEs: Addiction, Respiratory depression...
Other AEs:
Addiction
Respiratory depression (serious|grade 5)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/005010s059lbl.pdf
50 mg 6 times / day multiple, subcutaneous
Recommended
Dose: 50 mg, 6 times / day
Route: subcutaneous
Route: multiple
Dose: 50 mg, 6 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
Other AEs: Addiction, Respiratory depression...
Other AEs:
Addiction
Respiratory depression (serious|grade 5)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
10 mg/mL multiple, intravenous
Recommended
Dose: 10 mg/mL
Route: intravenous
Route: multiple
Dose: 10 mg/mL
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
pregnant, adult
Health Status: pregnant
Age Group: adult
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
Other AEs: Withdrawal syndrome neonatal...
Other AEs:
Withdrawal syndrome neonatal
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
10 mg/mL multiple, intravenous
Recommended
Dose: 10 mg/mL
Route: intravenous
Route: multiple
Dose: 10 mg/mL
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
Other AEs: Addiction, Respiratory depression...
Other AEs:
Addiction
Respiratory depression (serious|grade 5)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Hyperreflexia 1 patient
10 g single, oral
Overdose
Dose: 10 g
Route: oral
Route: single
Dose: 10 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/17364646
unknown, 17 years
Health Status: unknown
Age Group: 17 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/17364646
Hypotension 1 patient
10 g single, oral
Overdose
Dose: 10 g
Route: oral
Route: single
Dose: 10 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/17364646
unknown, 17 years
Health Status: unknown
Age Group: 17 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/17364646
Myoclonus 1 patient
10 g single, oral
Overdose
Dose: 10 g
Route: oral
Route: single
Dose: 10 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/17364646
unknown, 17 years
Health Status: unknown
Age Group: 17 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/17364646
Respiratory depression 1 patient
10 g single, oral
Overdose
Dose: 10 g
Route: oral
Route: single
Dose: 10 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/17364646
unknown, 17 years
Health Status: unknown
Age Group: 17 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/17364646
Tremor 1 patient
10 g single, oral
Overdose
Dose: 10 g
Route: oral
Route: single
Dose: 10 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/17364646
unknown, 17 years
Health Status: unknown
Age Group: 17 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/17364646
Respiratory depression 2 patients
50 mg single, intrathecal
Dose: 50 mg
Route: intrathecal
Route: single
Dose: 50 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/7923521
unknown, 24 - 81 years
Health Status: unknown
Age Group: 24 - 81 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/7923521
Muscle twitching 1 patient
Disc. AE
1000 mg 1 times / day multiple, intramuscular
Highest studied dose
Dose: 1000 mg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 1000 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3941530/
unhealthy, 37 years
Health Status: unhealthy
Age Group: 37 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/3941530/
Tremor 1 patient
Disc. AE
1000 mg 1 times / day multiple, intramuscular
Highest studied dose
Dose: 1000 mg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 1000 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3941530/
unhealthy, 37 years
Health Status: unhealthy
Age Group: 37 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/3941530/
Hallucinations 3 patients
600 mg 1 times / day multiple, intravenous
Highest studied dose
Dose: 600 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11772223
unknown, 44 years
Health Status: unknown
Age Group: 44 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/11772223
Jitteriness 3 patients
600 mg 1 times / day multiple, intravenous
Highest studied dose
Dose: 600 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11772223
unknown, 44 years
Health Status: unknown
Age Group: 44 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/11772223
Seizures 3 patients
600 mg 1 times / day multiple, intravenous
Highest studied dose
Dose: 600 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11772223
unknown, 44 years
Health Status: unknown
Age Group: 44 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/11772223
Withdrawal syndrome neonatal
50 mg 6 times / day multiple, intramuscular
Recommended
Dose: 50 mg, 6 times / day
Route: intramuscular
Route: multiple
Dose: 50 mg, 6 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
pregnant, adult
Health Status: pregnant
Age Group: adult
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
Withdrawal syndrome neonatal
50 mg 6 times / day multiple, oral
Recommended
Dose: 50 mg, 6 times / day
Route: oral
Route: multiple
Dose: 50 mg, 6 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/005010s059lbl.pdf
pregnant, adult
Health Status: pregnant
Age Group: adult
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/005010s059lbl.pdf
Withdrawal syndrome neonatal
50 mg 6 times / day multiple, subcutaneous
Recommended
Dose: 50 mg, 6 times / day
Route: subcutaneous
Route: multiple
Dose: 50 mg, 6 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
pregnant, adult
Health Status: pregnant
Age Group: adult
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
Addiction
50 mg 6 times / day multiple, intramuscular
Recommended
Dose: 50 mg, 6 times / day
Route: intramuscular
Route: multiple
Dose: 50 mg, 6 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
Respiratory depression serious|grade 5
50 mg 6 times / day multiple, intramuscular
Recommended
Dose: 50 mg, 6 times / day
Route: intramuscular
Route: multiple
Dose: 50 mg, 6 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
Addiction
50 mg 6 times / day multiple, oral
Recommended
Dose: 50 mg, 6 times / day
Route: oral
Route: multiple
Dose: 50 mg, 6 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/005010s059lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/005010s059lbl.pdf
Respiratory depression serious|grade 5
50 mg 6 times / day multiple, oral
Recommended
Dose: 50 mg, 6 times / day
Route: oral
Route: multiple
Dose: 50 mg, 6 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/005010s059lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/005010s059lbl.pdf
Addiction
50 mg 6 times / day multiple, subcutaneous
Recommended
Dose: 50 mg, 6 times / day
Route: subcutaneous
Route: multiple
Dose: 50 mg, 6 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
Respiratory depression serious|grade 5
50 mg 6 times / day multiple, subcutaneous
Recommended
Dose: 50 mg, 6 times / day
Route: subcutaneous
Route: multiple
Dose: 50 mg, 6 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
Withdrawal syndrome neonatal
10 mg/mL multiple, intravenous
Recommended
Dose: 10 mg/mL
Route: intravenous
Route: multiple
Dose: 10 mg/mL
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
pregnant, adult
Health Status: pregnant
Age Group: adult
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
Addiction
10 mg/mL multiple, intravenous
Recommended
Dose: 10 mg/mL
Route: intravenous
Route: multiple
Dose: 10 mg/mL
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
Respiratory depression serious|grade 5
10 mg/mL multiple, intravenous
Recommended
Dose: 10 mg/mL
Route: intravenous
Route: multiple
Dose: 10 mg/mL
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1946
inhibitor
2217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP2B6
776

CYP2C19
1119
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP2C19
1119
 yes
CYP2B6
776
 yes
likely (co-administration study)
Comment: The concomitant use of DEMEROL Injection and CYP3A4 or CYP2B6 inhibitors can increase the plasma concentration of meperidine, resulting in increased or prolonged opioid effects; The concomitant use of DEMEROL Injection and CYP3A4 inducers, or CYP2B6 inducers can decrease the plasma concentration of meperidine
Page: 20.0
CYP3A4
1946
 yes
likely (co-administration study)
Comment: The concomitant use of DEMEROL Injection and CYP3A4 or CYP2B6 inhibitors can increase the plasma concentration of meperidine, resulting in increased or prolonged opioid effects; The concomitant use of DEMEROL Injection and CYP3A4 inducers, or CYP2B6 inducers can decrease the plasma concentration of meperidine
Page: 20.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
2263
Sourcing

Sourcing

Vendor/AggregatorIDURL
3B Scientific (Wuhan) Corp
3B2-3283
http://www.3bsc.com/index/pro_info.php?id=76334
Ambinter
Amb17939801
http://www.ambinter.com/reference/17939801
Aurora Fine Chemicals LLC
A17.902.511
http://online.aurorafinechemicals.com/info?ID=A17.902.511
ChemMol
99111237
http://www.chemmol.com/chemmol/99111237.html
Clearsynth
CS-ED-00291
https://www.clearsynth.com/en/CSED00291.html
Clearsynth
CS-R-00538
https://www.clearsynth.com/en/CSR00538.html
Debye Scientific
DB-053051
http://www.debyesci.com/cas_57-42-1.html
LGC Standards
LGCAMP0315.11-01
https://www.lgcstandards.com/US/en/p/LGCAMP0315.11-01
LGC Standards
LGCAMP0315.11-02
https://www.lgcstandards.com/US/en/p/LGCAMP0315.11-02
Sigma-Aldrich
610593_SIAL
https://www.sigmaaldrich.com/catalog/product/sial/610593?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
M-035_CERILLIAN
https://www.sigmaaldrich.com/catalog/product/cerillian/m035?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sinfoo Biotech
S012160
http://www.sinfoobiotech.com/product/1015558
Smolecule
S577894
https://www.smolecule.com/products/s577894
PubMed

PubMed

TitleDatePubMed
Comparison of colonoscopies performed under sedation with propofol or with midazolam or without sedation.
2003
Demographics, assessment and management of pain in the elderly.
2003
Leptospirosis: skin wounds and control strategies, Thailand, 1999.
2002-12
Intraperitoneal pethidine versus intramuscular pethidine for the relief of pain after laparoscopic cholecystectomy: randomized trial.
2002-12
Plication darn for the repair of inguinal hernia. A university hospital experience.
2002-11
[Long-memory of labor pain].
2002-10-14
Characterisation of silent and active genes for a variable large protein of Borrelia recurrentis.
2002-10-14
Comparison of intravenous ketorolac and meperidine in the treatment of biliary colic.
2002-10
The low normothermia concept--maintaining a core body temperature between 36 and 37 degrees C in acute stroke unit patients.
2002-10
Two in one: patient-controlled epidural analgesia (PCEA) to prevent erection and control pain in adult hypospadias-surgery patients.
2002-09
Can ketamine potentiate the analgesic effect of epidural morphine, preincisional or postincisional administration?
2002-09
Effects of intravenous opioids on eye movements in humans: possible mechanisms.
2002-09
Retroperitoneal laparoscopic radical nephrectomy and nephroureterectomy and comparison with open surgery.
2002-09
Application of gas chromatography-surface ionization organic mass spectrometry to forensic toxicology.
2002-08-25
Laparoscopic hysterectomy versus abdominal hysterectomy: a controlled study of clinical and functional outcomes.
2002-08
Pulmonary function in infants exposed to pethidine.
2002-08
Selegiline: a second look. Six years later: too risky in Parkinson's disease.
2002-08
Synergistic sedation with midazolam and propofol versus midazolam and pethidine in colonoscopies: a prospective, randomized study.
2002-08
Upper gastrointestinal endoscopic ultrasound and its impact on patient management: 1990-2000.
2002-08
A prospective randomized trial comparing patient-controlled sedation using propofol and alfentanil and physician-administered sedation using diazepam and pethidine during transvaginal ultrasound-guided oocyte retrieval.
2002-08
Nasal administration of opioids for pain management in adults.
2002-08
Noninvasive anesthesia, analgesia and radiation-free extracorporeal shock wave lithotripsy for stones in the most distal ureter: experience with 165 patients.
2002-08
Primary thoracoscopic evaluation of pleural effusion with local anesthesia: an alternative approach.
2002-07-13
Mini cholecystectomy now a day stay surgery: anaesthetic management with multi modal analgesia.
2002-07
Severe hypokalaemia secondary to dicloxacillin.
2002-07
Pruritus: a useful sign for predicting the haemodynamic changes that occur following administration of vancomycin.
2002-06
A thermal threshold testing device for evaluation of analgesics in cats.
2002-06
Intra-arterial injection of metoclopramide, midazolam, propofol and pethidine.
2002-06
Double-blind, randomized trial comparing Harmonic Scalpel hemorrhoidectomy, bipolar scissors hemorrhoidectomy, and scissors excision: ligation technique.
2002-06
Lack of microbiological concordance between bone and non-bone specimens in chronic osteomyelitis: an observational study.
2002-05-16
Liquid-phase microextraction of protein-bound drugs under non-equilibrium conditions.
2002-05
Parenteral opioids for labor pain relief: a systematic review.
2002-05
Transdermal fentanyl for the management of acute pancreatitis pain.
2002-05
Anxiolytic premedication reduces preoperative anxiety and pain during oocyte retrieval. A randomized double-blinded placebo-controlled trial.
2002-05
Next generation of everyday analgesics.
2002-04-10
A placebo-controlled, randomized trial of droperidol versus metoclopramide for outpatients undergoing gynecological laparoscopy under conscious sedation.
2002-04
Use of opioid analgesics in a patient with chronic abdominal pain.
2002-04
Infective endocarditis: too ill to be operated?
2002-04
Improved procedure of colonoscopy under accompanying music therapy.
2002-03-28
[Survey of anesthesia practice in Morocco].
2002-01
Clinical experience and results of ESWL treatment for 3,093 urinary calculi with the Storz Modulith SL 20 lithotripter at the Singapore general hospital.
2002
Prevention and treatment of respiratory syncytial virus bronchiolitis and postbronchiolitic wheezing.
2002
A novel approach to the prevention of postoperative delirium in the elderly after gastrointestinal surgery.
2002
Intrathecal pethidine as sole anaesthetic agent for operative procedures of the lower limb, inguinal area and perineum.
2001-12
Morphine, pethidine and buprenorphine disposition in the cat.
2001-12
[Comparison of vaginal misoprostol and oxytocin for labor induction in post-term pregnancy].
2001-12
[Prospective double-blind randomized trial of cryoanalgesia: experimental and clinical study].
2001-11
Upper and mid-ureteric stones: a prospective unrandomized comparison of retroperitoneoscopic and open ureterolithotomy.
2001-11
Post operative pain therapy: a survey of prescribing patterns and adequacy of analgesia in Ibadan, Nigeria.
2001-03
[Anesthesia and analgesia for lower limb amputation].
2001
Patents

Patents

20010004644
50
JP2000501709A
76
JP2003522127A
12
JP2004527491A
37
JP2005530798A
42
JP2009526755A
475
JP4642467B2
32
JP4790415B2
14
JP4800219B2
66

Sample Use Guides

In Vivo Use Guide
Oral: 50 to 100 mg every 4 hours as needed. IV,IM,subcutaneously: 25 to 100 mg every 4 hours as needed. Continuous IV: 15 to 35 mg/hr.
Route of Administration: Other
In Vitro Use Guide
Pethidine's stimulant action on the 22-day pregnant rat isolated uterus does not involve receptors sensitive to methysergide and is unlikely to involve the synthesis and release of endogenous prostaglandins. Maximal stimulant response occurred with 40 ug/ml.
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:50:43 GMT 2025
Edited
by admin
on Mon Mar 31 17:50:43 GMT 2025
Record UNII
N8E7F7Q170
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PETHIDINE HYDROCHLORIDE
EP   MART.   WHO-DD   WHO-IP  
Preferred Name English
MEPERIDINE HYDROCHLORIDE
MI   ORANGE BOOK   USAN   USP   VANDF  
USAN  
Official Name English
DEMEROL
Brand Name English
MEPERIDINE HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
4-PIPERIDINECARBOXYLIC ACID, 1-METHYL-4-PHENYL-, ETHYL ESTER, HYDROCHLORIDE
Common Name English
NSC-400479
Code English
PETHIDINE HYDROCHLORIDE [WHO-IP]
Common Name English
PETHIDINE HYDROCHLORIDE [EP IMPURITY]
Common Name English
MEPERIDINE HYDROCHLORIDE [MI]
Common Name English
PETHIDINE HYDROCHLORIDE [EP MONOGRAPH]
Common Name English
MEPERIDINE HYDROCHLORIDE [ORANGE BOOK]
Common Name English
MEPERIDINE HYDROCHLORIDE CII [USP-RS]
Common Name English
PETHIDINE HYDROCHLORIDE [MART.]
Common Name English
MEPERGAN COMPONENT MEPERIDINE HYDROCHLORIDE
Common Name English
NIH 10522
Code English
MEPERIDINE HYDROCHLORIDE [USAN]
Common Name English
MEPERIDINE HYDROCHLORIDE CII
USP-RS  
Common Name English
MEPERIDINE HCL
Common Name English
PETHIDINE HYDROCHLORIDE [JAN]
Common Name English
PETHIDINI HYDROCHLORIDUM [WHO-IP LATIN]
Common Name English
MEPERIDINE HYDROCHLORIDE [VANDF]
Common Name English
Ethyl 1-methyl-4-phenylisonipecotate hydrochloride
Systematic Name English
Pethidine hydrochloride [WHO-DD]
Common Name English
Classification Tree Code System Code
DEA NO. 9230
Created by admin on Mon Mar 31 17:50:43 GMT 2025 , Edited by admin on Mon Mar 31 17:50:43 GMT 2025
NCI_THESAURUS C67413
Created by admin on Mon Mar 31 17:50:43 GMT 2025 , Edited by admin on Mon Mar 31 17:50:43 GMT 2025
Code System Code Type Description
EPA CompTox
DTXSID30950620
Created by admin on Mon Mar 31 17:50:43 GMT 2025 , Edited by admin on Mon Mar 31 17:50:43 GMT 2025
PRIMARY
DAILYMED
N8E7F7Q170
Created by admin on Mon Mar 31 17:50:43 GMT 2025 , Edited by admin on Mon Mar 31 17:50:43 GMT 2025
PRIMARY
CHEBI
31984
Created by admin on Mon Mar 31 17:50:43 GMT 2025 , Edited by admin on Mon Mar 31 17:50:43 GMT 2025
PRIMARY
SMS_ID
100000091068
Created by admin on Mon Mar 31 17:50:43 GMT 2025 , Edited by admin on Mon Mar 31 17:50:43 GMT 2025
PRIMARY
NSC
400479
Created by admin on Mon Mar 31 17:50:43 GMT 2025 , Edited by admin on Mon Mar 31 17:50:43 GMT 2025
PRIMARY
ChEMBL
CHEMBL607
Created by admin on Mon Mar 31 17:50:43 GMT 2025 , Edited by admin on Mon Mar 31 17:50:43 GMT 2025
PRIMARY
DRUG BANK
DBSALT000628
Created by admin on Mon Mar 31 17:50:43 GMT 2025 , Edited by admin on Mon Mar 31 17:50:43 GMT 2025
PRIMARY
CHEBI
6754
Created by admin on Mon Mar 31 17:50:43 GMT 2025 , Edited by admin on Mon Mar 31 17:50:43 GMT 2025
PRIMARY
NCI_THESAURUS
C635
Created by admin on Mon Mar 31 17:50:43 GMT 2025 , Edited by admin on Mon Mar 31 17:50:43 GMT 2025
PRIMARY
FDA UNII
N8E7F7Q170
Created by admin on Mon Mar 31 17:50:43 GMT 2025 , Edited by admin on Mon Mar 31 17:50:43 GMT 2025
PRIMARY
MERCK INDEX
m7186
Created by admin on Mon Mar 31 17:50:43 GMT 2025 , Edited by admin on Mon Mar 31 17:50:43 GMT 2025
PRIMARY Merck Index
PUBCHEM
5750
Created by admin on Mon Mar 31 17:50:43 GMT 2025 , Edited by admin on Mon Mar 31 17:50:43 GMT 2025
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
MEPERIDINE HYDROCHLORIDE
Created by admin on Mon Mar 31 17:50:43 GMT 2025 , Edited by admin on Mon Mar 31 17:50:43 GMT 2025
PRIMARY Description: A white, crystalline powder; odourless. Solubility: Very soluble in water; soluble in ethanol (~750 g/l) TS; practically insoluble in ether R. Category: Narcotic analgesic. Storage: Pethidine hydrochloride should be kept in a well-closed container, protected from light. Additional information: Even in the absence of light, Pethidine hydrochloride is gradually degraded on exposure to a humidatmosphere, the decomposition being faster at higher temperatures. Definition: Pethidine hydrochloride contains not less than 98.0% and not more than 101.0% of C15H21NO2,HCl, calculated withreference to the dried substance.
CAS
50-13-5
Created by admin on Mon Mar 31 17:50:43 GMT 2025 , Edited by admin on Mon Mar 31 17:50:43 GMT 2025
PRIMARY
RS_ITEM_NUM
1383001
Created by admin on Mon Mar 31 17:50:43 GMT 2025 , Edited by admin on Mon Mar 31 17:50:43 GMT 2025
PRIMARY
EVMPD
SUB03726MIG
Created by admin on Mon Mar 31 17:50:43 GMT 2025 , Edited by admin on Mon Mar 31 17:50:43 GMT 2025
PRIMARY
RXCUI
103755
Created by admin on Mon Mar 31 17:50:43 GMT 2025 , Edited by admin on Mon Mar 31 17:50:43 GMT 2025
PRIMARY RxNorm
ECHA (EC/EINECS)
200-013-3
Created by admin on Mon Mar 31 17:50:43 GMT 2025 , Edited by admin on Mon Mar 31 17:50:43 GMT 2025
PRIMARY
Related Record Type Details
Structure of MEPERIDINE
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of MEPERIDINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966